July 19 (Bloomberg) -- A vaginal gel containing Gilead Sciences Inc.’s AIDS drug Viread cut HIV infections by as much as 54 percent in a trial in South Africa, the first time such a product has protected women after six previous gels failed.
July 19 (Bloomberg) -- A vaginal gel containing Gilead Sciences Inc.’s AIDS drug Viread cut HIV infections by as much as 54 percent in a trial in South Africa, the first time such a product has protected women after six previous gels failed.
